Mechanisms of resistance to CAR T cell therapies

Nathan Singh, Elena Orlando, Jun Xu, Jie Xu, Zev Binder, McKensie A. Collins, Donald M. O'Rourke, J. Joseph Melenhorst

Research output: Contribution to journalReview articlepeer-review

21 Scopus citations


Chimeric antigen receptor (CAR)-engineered T cells have demonstrated remarkable success in the treatment of B cell malignancies. FDA approval of these therapies represents a watershed moment in the development of therapies for cancer. Despite the successes of the last decade, many patients will unfortunately not experience durable responses to CAR therapy. Emerging research has shed light on the biology responsible for these failures, and further highlighted the hurdles to broader success. Here, we review the recent research identifying how interactions between cancer cells and engineered immune cells result in resistance to CAR therapies.

Original languageEnglish
Pages (from-to)91-98
Number of pages8
JournalSeminars in Cancer Biology
StatePublished - Oct 2020


  • Chimeric antigen receptor
  • Resistance


Dive into the research topics of 'Mechanisms of resistance to CAR T cell therapies'. Together they form a unique fingerprint.

Cite this